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174Objective: Pulmonary ischemia and reperfusion during routine open heart surgery with cardiopulmonary bypass
can lead to pulmonary dysfunction and vasoconstriction, resulting in a high morbidity and mortality. We inves-
tigated whether ischemia/reperfusion-induced pulmonary dysfunction after full-flow cardiopulmonary bypass
could be prevented by the infusion of leukocyte-depleted hypoxemic blood during the early phase of reperfusion
(terminal leukocyte-depleted lung reperfusion) and whether the benefits of this method were nullified by using
hyperoxemic blood for reperfusion.
Methods: Twenty-one neonatal piglets underwent 180 minutes of full-flow cardiopulmonary bypass with pulmo-
nary artery occlusion, followed by reperfusion. The piglets were divided into 3 groups of 7 animals. In group I,
uncontrolled reperfusion was achieved by unclamping the pulmonary artery. In contrast, pulmonary reperfusion
was done with leukocyte-depleted hyperoxemic blood in group II or with leukocyte-depleted hypoxemic blood in
group III for 15 minutes at a flow rate of 10 mL/min/kg before pulmonary artery unclamping. Then the animals
were monitored for 120 minutes to evaluate post-cardiopulmonary bypass pulmonary function.
Results: Group I developed pulmonary dysfunction that was characterized by an increased alveolar-arterial ox-
ygen difference (204  57.7 mm Hg), pulmonary vasoconstriction, and decreased static lung compliance. Ter-
minal leukocyte-depleted lung reperfusion attenuated post-cardiopulmonary bypass pulmonary dysfunction
and vasoconstriction when hypoxemic blood was used for reperfusion (alveolar-arterial oxygen difference,
162  61.0 mm Hg). In contrast, no benefit of terminal leukocyte-depleted lung reperfusion was detected after
reperfusion with hyperoxemic blood (alveolar-arterial oxygen difference, 207  60.8 mm Hg).
Conclusion: Reperfusion with leukocyte-depleted hypoxemic blood has a protective effect against ischemia/
reperfusion-induced pulmonary dysfunction by reducing endothelial damage, cytokine release, and leukocyte
activation. (J Thorac Cardiovasc Surg 2010;139:174-80)Pulmonary dysfunction after cardiac surgery that involves
cardiopulmonary bypass (CPB) still remains a major prob-
lem, resulting in poor alveolar oxygenation and increased
pulmonary vascular resistance (Rp) that requires prolonged
artificial ventilation and contributes to a high morbidity and
mortality.1,2 With respect to the pathogenesis of post-CPB
pulmonary dysfunction, CPB per se is known to cause
many changes by triggering the systemic inflammatory re-
sponse syndrome (SIRS).2-5 We previously reported on the
mechanism of these undesirable changes of lung function
after CPB in the Journal, with the major causes being acti-
vation of blood components and release of vasoactive
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The Journal of Thoracic and Cardiovascular Surghave a more severe inflammatory response to CPB than
adults.2 In the current era of advanced CPB technology, in-
cluding development of the membrane oxygenator, surface
coating methods, and downsizing of the pump circuit to al-
low priming without the need for donor blood, the extent of
SIRS due to CPB itself may have been minimized, but pul-
monary ischemia/reperfusion injury inherent to routine open
heart surgery remains a major cause of pulmonary dysfunc-
tion and pulmonary vasoconstriction.6,7 Although both the
heart and the lungs are exposed to ischemia/reperfusion in-
jury during cardiac surgery, protection against such injury
is only provided for the heart, and there is no established
therapeutic modality for prevention of postoperative pulmo-
nary dysfunction that can be routinely applied. Therefore, in
the setting of prolonged total CPB that is used to repair com-
plex cardiac malformations, especially in neonates, a reliable
and effective method for prevention of pulmonary ischemia/
reperfusion injury is greatly needed.
Pulmonary dysfunction after CPB is thought to largely oc-
cur during the early reperfusion period rather than during is-
chemia, and this pulmonary ischemia/reperfusion injury is
thought to be mainly caused by activated leukocytes duringery c January 2010
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A-aDO2 ¼ alveolar-arterial oxygen difference
CPB ¼ cardiopulmonary bypass
ET-1 ¼ endothelin-1
IL ¼ interleukin
LA ¼ left atrium
MPO ¼ myeloperoxidase
NOx ¼ nitrogen oxide
PA ¼ pulmonary artery
PMN ¼ polymorphonuclear neutrophil
Rp ¼ pulmonary vascular resistance
SIRS ¼ systemic inflammatory response
syndromeTLDLR ¼ terminal leukocyte-depleted lung
reperfusionWBC ¼ white blood cellP
Mthe early phase of pulmonary reperfusion.8,9 This implies
that successful management of ischemia/reperfusion-induced
pulmonary dysfunction may be achieved by controlling lung
reperfusion just at the onset of re-flow. By accepting the the-
ory that activated leukocytes and free radicals cause ischemia/
reperfusion-induced pulmonary dysfunction,7 we tested the
following hypotheses in a neonatal piglet model of prolonged
lung ischemia with full-flow CPB: (1) ischemia/reperfusion-
induced pulmonary dysfunction after CPB can be prevented
by terminal leukocyte-depleted lung reperfusion (TLDLR,
ie, initial pulmonary reperfusion with leukocyte-depleted
hypoxemic blood), and (2) the protective effect of TLDLR
against ischemia/reperfusion-induced pulmonary dysfunc-
tion would be nullified by reperfusion with hyperoxemic
blood instead of hypoxemic blood.
MATERIALS AND METHODS
Animals and Cardiopulmonary Bypass Preparation
Twenty-one neonatal piglets (Large White Landrace Duroc) weighing
13.2  1.9 kg (mean  standard deviation) were used for this study. Use
of these animals and the study protocol were approved by the animal welfare
committee of The Jikei University School ofMedicine. All animals received
humane care in compliance with the ‘‘Principles of Laboratory Animal
Care’’ formulated by the National Society for Medical Research and the
‘‘Guide for the Care and Use of Laboratory Animals’’ prepared by the Na-
tional Academy of Science and published by the National Institutes of
Health (publication 96-03, revised 1996).
Animals were sedated with intravenous thiopental sodium (10 mg/kg),
and endotracheal intubation was performed. Mechanical ventilation was
performed at a rate of 20 breaths/min and a tidal volume of 15 mL/kg
with an ACE-300 (ACOMA, Tokyo, Japan). General anesthesia was main-
tained with nitrous oxide (1 L/min), oxygen (1 L/min), and sevoflurane
(2.5%).
With the piglet in the supine position, the femoral artery was cannulated
for arterial access and the central venous line was advanced through the
femoral vein into the inferior vena cava. Arterial blood samples were drawn
periodically and analyzed by an i-STAT 300F (Fuso Pharmaceutical Indus-
tries, Ltd, Osaka, Japan). Midline sternotomy and pericardiotomy were per-The Journal of Thoracic and Caformed. After administration of heparin (300 U/kg), the arterial cannula was
placed in the right common carotid artery (Fem-Flex II cannula, Edwards
Lifesciences, Irvine, Calif) and the venous cannula was placed in the right
atrium (DLP angled metal tip [Pacifico] cannula, Medtronic, Inc,
Minneapolis, MN). The left atrium (LA) and pulmonary artery (PA) were
also cannulated to monitor the LA and PA pressures. An ultrasonic blood
flow meter (T201, Transonic Systems Inc, Ithaca, NY) was placed around
the main PA to measure PA flow. The extracorporeal circuit consisted of
a roller pump (Terumo Corp, Tokyo, Japan) and a membrane oxygenator
(Capiox RX05, Terumo Corp). This circuit was primed with 120 mL of
Ringer’s acetate solution, 40 mL of 20% albumin, 30 mL of 20%mannitol,
and 20 mL of 7% sodium bicarbonate, eliminating the need for donor blood
priming. Blood transfusion was not done because it has been reported that
transfusion can cause pulmonary dysfunction.10
Study Protocol and Groups
All piglets were subjected to 180 minutes of full-flow CPB with clamp-
ing of the main PA (to create pulmonary ischemia), starting from 5 minutes
after the onset of normothermic CPB at a flow rate of 100 mL/min/kg, and
followed by 25 minutes of pulmonary reperfusion on CPB (Figure 1). We
observed the piglets for 120 minutes after the termination of CPB. During
full-flow CPB with PA clamping, venting of the PA and right ventricle
was performed to ensure pulmonary ischemia, eliminate the influence of
collateral flow into the pulmonary circulation from systemic arteries, and
avoid right ventricular overdistension. We could remove the effect of bron-
chial blood flow by these ventings. Hematocrit was kept at 22% to 25%
during perfusion without blood transfusion by the application of hemofiltra-
tion. During CPB, the arterial partial pressure of oxygen was maintained be-
tween 200 and 300 mm Hg and pulmonary ventilation was stopped during
full-flow CPB. The heart was beating during CPB.
The piglets were divided into 3 groups by the mode of pulmonary reperfu-
sion. In group I, the clamp on the main PA was simply removed to allow un-
controlled pulmonary reperfusion for 25 minutes on CPB. This reperfusion
was uncontrolled systemic venous reperfusion at the flow of 10 mL/min/kg.
In group II, 180 minutes of full-flow CPB with PA occlusion was followed
by 15 minutes of TLDLR with leukocyte-depleted hyperoxemic blood from
the CPB circuit at a flow rate of 10 mL/min/kg. This oxygenated blood was
removed from the arterial line of the CPB, passed through a leukocyte-deplet-
ing filter (Pall LeukoGuard BC2 Cardioplegia Filter, Pall Corporation, East
Hills, NY), and administered through a cannula that had been inserted into
the main PA distal to the clamping site. In group II, the partial pressure of ox-
ygen in the pulmonary reperfusate was 257 29.3 mmHg. After 15 minutes
of selective pulmonary reperfusion, themain PAwas declamped, followed by
another 10 minutes of uncontrolled reperfusion on CPB and 120 minutes of
observation after the termination of CPB. In group III, after 180 minutes of
full-flow CPB with PA occlusion, 15 minutes of TLDLR was also performed
with leukocyte-depleted hypoxemic blood from the venous reservoir of the
CPB circuit instead of hyperoxemic blood. In group III, the partial pressure
of oxygen in the pulmonary reperfusate was 50.0 12.6 mm Hg.
Assessment of Pulmonary Function
We evaluated various parameters of lung function, including the alveo-
lar-arterial oxygen difference (A-aDO2), static lung compliance, and Rp.
Measurements were obtained before CPB (baseline) and 15 minutes, 1
hour, and 2 hours after the termination of CPB.
A-aDO2 was calculated by using the following formula:
A-aDo2 ðmm HgÞ ¼ Fio23 713Paco2=0:8Pao2
whereFIO2 is the inspired fraction of oxygen, PaCO2 is the arterial partial pres-
sure of carbon dioxide, and PaO2 is the arterial partial pressure of oxygen.
Static lung compliance was determined from duplicate expirations using
a volume-limited ventilator. The expiratory plateau pressure was recorded
for 2 breaths each at 4 different tidal volumes without positive end-rdiovascular Surgery c Volume 139, Number 1 175
FIGURE 2. Before CPB, WBC counts were similar in the 3 groups. After
pulmonary reperfusion, there was no decrease of WBC in group I, but WBC
decreased by 50% in group II and by 40% in group III (*P<.05 vs group II;
yP<.05 vs group III; #P<.05 vs pre-CPB).WBC,White blood cell; CPB,
cardiopulmonary bypass.
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FIGURE 1. In group I, the clamp on the main PA was removed after
180minutes of total CPB, followed by monitoring for another 120 minutes
to evaluate pulmonary function. In groups II and III, modified reperfusion
was done for 15minutes before removing the main PA clamp. CPB, Cardio-
pulmonary bypass; PA, pulmonary artery.
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Mexpiratory pressure. Static lung compliance was calculated as the change of
volume/change of pressure (mL/cm H2O).
PA and LA pressures were monitored during the experiment, and PA
flow was measured by the ultrasonic blood flow meter. These data were
used to calculate Rp by the following formula:
Rp

dynes 3 sec1 3 cm5
 ¼ ðPA pressureLA pressureÞ=PA flow $ 80
Measurement of Plasma Parameters
Pulmonary venous blood samples were obtained at the following 5
times: before CPB (baseline), just before the termination of CPB, and
15 minutes, 1 hour, and 2 hours after the termination of CPB. Then the
plasma concentrations of nitrogen oxide (NOx) and endothelin-1 (ET-1)
were measured.
Measurement of Lung Tissue Parameters
Wedge biopsy of the lung was done at the same 5 sampling points to pul-
monary venous blood samples. Lung tissue was homogenized to measure
myeloperoxidase (MPO) activity and interleukin (IL)-6 level. The remain-
ing specimen was weighed and dried to a constant weight by heating at
80C for 24 hours, after which the dry weight was measured. Then the tissue
water content was measured and expressed as a percentage using the follow-
ing formula:
Lung tissue water content ð%Þ ¼ ð1dry weight=wet weightÞ3 100
We confirmed in the control group that the volume of specimen was too
small to influence the lung function.
Statistical Analysis
Statistical analysis was performed with STATA software (College
Station, TX). Data are expressed as the mean  standard deviation.
Repeated-measures analysis of variance, followed by the Bonferroni
multiple comparison test, was used to analyze group effects and time effects.
RESULTS
White Blood Cell Counts
Before CPB, white blood cell (WBC) counts were sim-
ilar in the 3 groups (Figure 2). After pulmonary reperfu-
sion, there was no decrease of WBC in group I, but,
WBC decreased by 50% in group II and by 40% in176 The Journal of Thoracic and Cardiovascular Surggroup III (P< .05). WBC counts were significantly de-
creased by the leukocyte-depleting filter. The efficacy
of leukocyte depletion was not dependent on oxygen ten-
sion, and, WBC counts in the reperfusion solution were
also decreased by 90%.
Pulmonary Function
Alveolar-arterial oxygen difference. Before CPB, there
was no significant difference of A-aDO2 among the 3 groups
(Figure 3, A). A-aDO2 deteriorated significantly after total
CPB in group I and showed a significant increase compared
with the pre-CPB value throughout the observation period
(pre-CPB, 130  28.4 mm Hg; post-CPB 2 hours, 204 
57.7 mm Hg; P< .05). In contrast, A-aDO2 did not increase
after CPB and was lower in group III than in the other 2
groups (pre-CPB, 130  65.9 mm Hg; post-CPB 2 hours,
162  61.0 mm Hg). The results showing that A-aDO2 in
group II was comparable to that of group I suggested that
perfusion with hyperoxemic blood instead of hypoxemic
blood nullified the benefits of TLDLR.
Lung compliance. There was no significant difference of
lung compliance among the 3 groups before CPB, but com-
pliance was significantly reduced in group I after CPB com-
pared with the baseline value and stayed low throughout the
observation period (Figure 3, B). In contrast, impairment of
lung compliance was significantly less marked in group III
compared with group I, whereas the improvement of lung
compliance was inconsistent in group II (P< .05 between
group I and III).
Pulmonary vascular resistance. Rp increased signifi-
cantly after CPB in group I, although there was no difference
of Rp among the groups before CPB (Figure 3, C). This
indicates that ischemia/reperfusion-induced pulmonary
vasoconstriction occurred after total CPB. The increase ofery c January 2010
FIGURE 3. A, A-aDO2 was measured before CPB and 15 minutes, 1 hour,
and 2 hours after CPB (#P< .05 vs pre-CPB). B, Lung compliance was
measured before CPB and 15 minutes, 1 hour, and 2 hours after CPB (yP
< .05 vs group III). C, Rp was measured before CPB and 15 minutes, 1
hour, and 2 hours after CPB (*P< .05 vs group II, yP< .05 vs group III,
#P< .05 vs pre-CPB). A-aDO2, Alveolar-arterial oxygen difference; CPB,
cardiopulmonary bypass.
FIGURE 4. Pulmonary venous blood samples were obtained from the LA
at the following 5 times: before CPB (baseline), just before the termination
of CPB, and 15 minutes, 1 hour, and 2 hours after the termination of CPB.
NOx (A) and ET-1 (B) (*P< .05 vs group II, #P< .05 vs pre-CPB). NOx,
Nitrogen oxide; CPB, cardiopulmonary bypass.
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MRp after CPB was significantly smaller in groups II and III
(P< .05).
Pulmonary Venous Blood Parameters
Plasma nitrogen oxide concentration. There were no dif-
ferences in the plasma NOx level among the 3 groups before
CPB (28.8 17.1 in group I, 26.8 9.77 in group II, 27.4
3.54 mmol/L in group III) (Figure 4, A). NOx gradually in-
creased after the start of pulmonary reperfusion in groups
I and II, whereas NOx was unaltered in group III and lower
than in the other 2 groups.
Plasma endothelin-1 concentration. Therewere no differ-
ences in ET-1 levels among the 3 groups before CPB and just
before reperfusion (Figure 4, B). In group I, ET-1 remained
higher than in the other groups after termination of CPB,
whereas it returned to the pre-CPB range in groups II and III.rdiovascular Surgery c Volume 139, Number 1 177
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MLung Tissue Parameters
Myeloperoxidase activity. Until the end of CPB, there was
no increase of MPO activity or differences among the 3
groups (Figure 5, A). In groups I and II, MPO activity
showed a considerable increase after the termination of
CPB, whereas it was slightly lower in group III than in the
other groups (P< .05 between group II and III).
Interleukin-6 level. In group I, IL-6 showed a sudden in-
crease after the onset of pulmonary reperfusion. This in-
crease of IL-6 after reperfusion was less marked in groups
II and III (P< .05) (Figure 5, B).
Water content. No significant change of the water content
was detected during CPB in the 3 groups. Although the
water content increased during lung reperfusion in all
groups, the increase was smaller in groups II and III
compared with group I (Figure 5, C).FIGURE 5. Wedge biopsy of the lung was done to measure MPO activity
(A), IL-6 (B), and water content (C) in lung tissue (*P<.05 vs group II, yP
< .05 vs group III, # P< .05 vs pre-CPB). MPO, Myeloperoxidase; CPB,
cardiopulmonary bypass.DISCUSSION
The present study confirmed that pulmonary dysfunction,
characterized by reduced alveolar oxygenation and lung
compliance associated with pulmonary vasoconstriction, oc-
curred after full-flow CPB in a neonatal piglet model of pro-
longed lung ischemia, which was used to simulate pediatric
open heart surgery. We demonstrated that a) this ischemia/
reperfusion-induced pulmonary dysfunction can be pre-
vented by terminal leukocyte-depleted lung reperfusion
(TLDLR), which involves initial pulmonary reperfusion
with leukocyte-depleted blood, and that b) the beneficial ef-
fect of TLDLR on ischemia/reperfusion-induced pulmonary
dysfunction was lost if hyperoxemic blood was used for re-
perfusion instead of hypoxemic blood. Given the concern
about the detrimental effects of hyperoxemic reperfusion,
we first confirmed the crucial importance of the oxygen ten-
sion during pulmonary reperfusion. The method examined
may be useful as a rescue strategy in the circumstances in
which pulmonary ischemia is unexpectedly prolonged, par-
ticularly in patients lacking sufficient bronchial or systemic
collateral flow into the pulmonary vasculature to avoid lung
ischemia during CPB. It is easy to perform this procedure
whenever required during the final minutes of pulmonary
ischemia. In clinical lung transplantation, Schnickel and
colleagues11 used a similar method of reperfusion with leu-
kocyte-depleted solution for 10 minutes. The results that we
obtained in this study were also similar to theirs, indicating
that the present model has a pathophysiology closely resem-
bling that of clinical CPB.
Pulmonary dysfunction is a well-known adverse effect of
CPB. CPB alters many factors simultaneously2-6 and causes
SIRS, including complement-mediated neutrophil activa-
tion,5,6 production of oxygen free radicals,3 and generation
of vasoactive mediators.4 Post-CPB lung complications2,4,6
cover a wide spectrum from gas-exchange abnormalities to
hemodynamic derangement. Acute pulmonary dysfunction178 The Journal of Thoracic and Cardiovascular Surgwas reported to occur after cardiac surgery in 0.4% to 3%
of patients undergoing CPB, and the associated mortality
rate is high (15%–70%).12,13 However, the latest advancesery c January 2010
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Min CPB systems and circuits have markedly reduced the con-
tribution of CPB per se to the pathogenesis of postoperative
pulmonary dysfunction, as indicated by a recent report of
no difference in the extent of SIRS and lung dysfunction be-
tween off-pump and on-pump coronary bypass surgery.14We
also confirmed in our pilot study (with a similar design to the
present protocol) that there was little pulmonary dysfunction
after partial CPB when lung perfusion was maintained at 10
mL/min/kg and a membrane oxygenator was used without
donor blood priming (unpublished data).
Another potential major determinant of post-CPB pulmo-
nary dysfunction is pulmonary ischemia/reperfusion in-
jury.15 Unlike other organs in the human body, the lungs
possess 2 blood supply networks with extensive anastomotic
connections. Nevertheless, the fact that CPB reduces perfu-
sion of the bronchial vessels raises concern about pulmonary
ischemia during total CPB. Careful management of the early
reperfusion period is important. Thiswas the rationale for our
concept of early leukocyte-depleted pulmonary reperfusion.
For the prevention or treatment of SIRS and acute pulmonary
dysfunction after CPB, several distinct strategies have been
used to protect against injury related to polymorphonuclear
neutrophils (PMNs), including pharmacologic interven-
tion16 and removal of WBCs from blood in the CPB circuit
by filtration.17 In most of the previous studies, however,
the leukocyte-depleting filter was connected to the arterial
line of the CPB circuit and was intended to reduce the total
number of circulating PMNs for amelioration of SIRS. In
our study, however, the leukocyte-depleting filter was only
placed in the pulmonary arterial line, and targeted leukocyte
depletion was more specific and efficient for preventing re-
perfusion injury. With respect to the optimal method of leu-
kocyte-depleted reperfusion, there have been no reports
about the influence of the duration of leukocyte depletion.
In our pilot study, leukocyte depletion was performed for
5, 15, and 30 minutes in the same ischemia/reperfusion
model. There was a negligible effect of depletion for 5 min-
utes, but comparable effects of depletion for 15 and 30 min-
utes. This suggests that leukocyte depletion for 15 minutes
may be adequate if the ischemic period is approximately 3
hours. We also considered the influence of the flow rate dur-
ing pulmonary reperfusion. We hypothesized that low-flow
reperfusion rather than rapid reperfusion might ameliorate
pulmonary dysfunction after CPB. The flow rate used by
Halldorsson and colleagues18 in their experiments on ische-
mia/reperfusion injury in pigs was approximately 20 mL/
min/kg, so we performed PA reperfusion at 10 mL/min/kg,
whichwas approximately half of that rate. They also reported
a similar benefit of leukocyte-depleted lung reperfusion in
a regional lung ischemiamodel without CPB.18 In that study,
they clamped the right PAand took blood from femoral artery
that was passed through a leukocyte-depleting filter before
being returned to the right PA. Although their basic concept
and method seem to be similar to ours, they demonstratedThe Journal of Thoracic and Caa benefit of lung reperfusion with hyperoxemic blood, unlike
the present study in which we found that the use of hyperoxe-
mic blood was detrimental and nullified the benefit of leuko-
cyte depletion. This suggests that pulmonary dysfunction
after CPB may be influenced by the fact that CPB itself
causes the onset of SIRS, thusmaking the lungsmore suscep-
tible to oxidative injury during hyperoxemic reperfusion.
Activated PMNs can release a number of proteolytic en-
zymes and oxidative agents into the systemic circulation
and lung tissue. These substances include PMN elastase,8,16
oxygen free radicals, and MPO.19 MPO is an indicator of the
production of reactive oxygen species and an index of neu-
trophil activation. MPO activity was lower in group III than
in groups I and II, which implies that the low oxygen con-
centration inhibited MPO release by affecting neutrophil
function. It has been proposed that an increase of free radi-
cals represents a potential risk factor for pulmonary dysfunc-
tion after CPB.20 In fact, hyperoxic CPB is widely used in
cardiac surgery, and there is some concern about whether ex-
cessive oxygenation may induce the production of oxygen-
derived free radicals. It has been suggested that hyperoxic
CPB increases oxygen free radical damage to the lungs com-
pared with normoxic CPB.21 The present study also demon-
strated that hypoxemic blood was superior to hyperoxemic
blood as the pulmonary reperfusate in terms of protecting
the lungs.
Serum and bronchoalveolar lavage fluid levels of IL-6 are
sensitive indicators of the severity of pulmonary dysfunction
and are correlated with postoperative morbidity.5,22 In this
study,wemeasured the IL-6 level in lung tissue rather than se-
rum because the serum concentration of IL-6 after CPB is
influenced by many factors in addition to pulmonary inflam-
mation, for example, a considerable amount of IL-6 can be re-
leased from organs such as the heart and muscles. This study
showed that groups II and III had lower lung tissue IL-6 levels
than group I, suggesting that leukocyte depletion is an effec-
tivemethodof decreasingpulmonary inflammation afterCPB.
Pulmonary vasoconstriction has been demonstrated after
CPB, both experimentally5,23 and clinically.4,6,24 Some re-
ports have suggested a role of ischemia/reperfusion-induced
pulmonary endothelial cell dysfunction, possibly because of
local activation of the complement-leukocyte system lead-
ing to free radical generation.4-6,23 The endothelium has an
important role in regulating vascular tone by releasing
vasoactive mediators, including endothelin, nitric oxide,
prostacyclin, and thromboxanes. It is well known that the
pulmonary endothelium is the initial target of extracellular
free radical attack, resulting in endothelium-derived vaso-
constriction.25 By measurement of plasma ET-1 and NOx
levels, we confirmed that lung ischemia/reperfusion during
total CPB produced pulmonary vasoconstriction that was re-
lated to the severity of pulmonary endothelial dysfunction.
Leukocyte depletion during reperfusion markedly reduced
post-CPB pulmonary vasoconstriction by avoiding therdiovascular Surgery c Volume 139, Number 1 179
Perioperative Management Kagawa et al
P
Maccumulation of activated leukocytes that could cause endo-
thelial dysfunction.
CONCLUSIONS
To our knowledge, this is the first study to evaluate the ef-
fect of leukocyte-depleted pulmonary reperfusion in piglets
after full-flow CPB with PA occlusion and no donor blood
priming. We showed that ischemia/reperfusion-induced pul-
monary dysfunction after CPB can be prevented by initial
pulmonary reperfusion with leukocyte-depleted hypoxemic
blood, which reduces the inflammatory response, endothe-
lial damage, and leukocyte activation. Because of the limita-
tions of this study, including the small number of animals
and large variability of measured values, many comparisons
did not reach statistical significance and we could not clarify
the causes of this type of lung injury or the mechanism un-
derlying the benefits of leukocyte depletion. However, this
study provides a rationale for protection of the lungs during
CPB and should promote further research.
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